Trial Profile
Randomised double blinded placebo controlled trial to assess the effect of oral nicotinamide on numbers of new nonmelanoma skin cancers in immune competent adult patients with a history of at least two histologically confirmed nonmelanoma skin cancers within the previous five years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Nicotinamide (Primary)
- Indications Skin cancer
- Focus Therapeutic Use
- Acronyms ONTRAC
- 16 Feb 2016 Primary endpoint has been met (Disease occurrence rate) as per the Results published in the Annals of Internal Medicine.
- 16 Feb 2016 Results published in the Annals of Internal Medicine
- 22 Oct 2015 Results published in the New England Journal of Medicine